Tessellate Bio Limited

Tessellate Bio Ltd, a small, active company based in London, UK, was founded two years ago and employs eight people. With £1,113,020 in assets and a virtual address, the company operates with two directors and no reported owners. It’s an irregular importer of pharmaceutical products, with just two months of imports recorded, the latest in February 2024.

The company’s website describes Tessellate Bio as redefining synthetic lethality, aiming to turn cancer patients into survivors. It’s an innovator in this field, exploring new interactions and creating a pipeline of precision medicines. The company is committed to precision oncology, incorporating biomarker discovery and companion diagnostics early in its programs. A world-class team, led by experienced drug hunters, shapes the science and pipeline. Recent news includes a partnership with Boehringer Ingelheim to develop cancer treatments and the appointment of Lara Boyd as Chief Business Officer.

Financially, Tessellate Bio Ltd presents a mixed picture. While current assets remain steady at £850,000, net liabilities have deepened to -£3.6 million. Bank borrowings are significant at £4.5 million, and cash reserves are a modest £350,000. Creditors remain high at £4.5 million, and trade debtors are £500,000. The company meets the criteria for a small business, with turnover under £10.2 million, assets under £5.1 million, and fewer than 50 employees. The lack of a reported auditor is typical for a small company. The significant net liabilities and reliance on bank borrowings suggest the company is burning through cash, but the recent partnership could provide a much-needed infusion of capital.

Registered in England/Wales under the registration number 14207136, with a registered address at SE1 2AU, United Kingdom, London, 4 More London, Riverside.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.